HK1209750A1 - Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Info

Publication number: HK1209750A1
Authority: HK; Hong Kong
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; thienopyrimidine derivatives; thienopyrimidine
Prior art date: 2013-12-23

Application number

HK15110667.4A

Other languages

English (en)

Chinese (zh)

Inventor

Kotschy Andrs

Zoltn Szlvik

Mrton Cskei

Attila Paczal

Zoltn Szab

Szabolcs Sipos

Gbor Radics

Gnes Proszenyk

Balzs Blint

Alain Bruno

Olivier Geneste

James Edward Paul Davidson

James Brooke Murray

I-Jen Chen

Franoise Perron-Sierra

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-23

Filing date

2015-10-28

Publication date

2016-04-08

2015-10-28 Application filed by Servier Lab filed Critical Servier Lab

2016-04-08 Publication of HK1209750A1 publication Critical patent/HK1209750A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hematology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HK15110667.4A 2013-12-23 2015-10-28 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them HK1209750A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1363500A FR3015483B1 (fr)	2013-12-23	2013-12-23	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
HK1209750A1 true HK1209750A1 (en)	2016-04-08

Family

ID=50829005

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK15110667.4A HK1209750A1 (en)	2013-12-23	2015-10-28	Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
HK15112389.7A HK1211583A1 (en)	2013-12-23	2015-12-16	New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK15112389.7A HK1211583A1 (en)	2013-12-23	2015-12-16	New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (48)

Country	Link
US (3)	US9670227B2 (xx)
EP (1)	EP2886545B1 (xx)
JP (1)	JP5922215B2 (xx)
KR (1)	KR101636401B1 (xx)
CN (1)	CN104725397B (xx)
AP (1)	AP2014008127A0 (xx)
AR (1)	AR098906A1 (xx)
AU (1)	AU2014274644B2 (xx)
BR (1)	BR102014032336B1 (xx)
CA (1)	CA2875226C (xx)
CL (1)	CL2014003444A1 (xx)
CO (1)	CO7210068A1 (xx)
CR (1)	CR20140569A (xx)
CU (1)	CU24309B1 (xx)
CY (1)	CY1118058T1 (xx)
DK (1)	DK2886545T3 (xx)
DO (1)	DOP2014000282A (xx)
EA (1)	EA029601B1 (xx)
ES (1)	ES2594377T3 (xx)
FR (1)	FR3015483B1 (xx)
GE (1)	GEP201706619B (xx)
GT (1)	GT201400297A (xx)
HK (2)	HK1209750A1 (xx)
HR (1)	HRP20161203T8 (xx)
HU (1)	HUE029654T2 (xx)
IL (1)	IL236143A (xx)
JO (1)	JO3193B1 (xx)
LT (1)	LT2886545T (xx)
MD (1)	MD4516C1 (xx)
ME (1)	ME02521B (xx)
MX (1)	MX351581B (xx)
MY (1)	MY185221A (xx)
NI (1)	NI201400150A (xx)
PE (1)	PE20151064A1 (xx)
PH (1)	PH12014000375B1 (xx)
PL (1)	PL2886545T3 (xx)
PT (1)	PT2886545T (xx)
RS (1)	RS55213B1 (xx)
RU (1)	RU2605403C2 (xx)
SA (1)	SA114360144B1 (xx)
SG (1)	SG10201408563UA (xx)
SI (1)	SI2886545T1 (xx)
TN (1)	TN2014000516A1 (xx)
TW (1)	TWI508969B (xx)
UA (1)	UA120341C2 (xx)
UY (1)	UY35915A (xx)
WO (1)	WO2015097123A1 (xx)
ZA (1)	ZA201409365B (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016065410A1 (en)	2014-10-29	2016-05-06	The Walter And Eliza Hall Institute Of Medical Research	Use of therapeutic agents
WO2016187723A1 (en) *	2015-05-27	2016-12-01	Pharmascience Inc.	Inhibitors of the tec kinase enzyme family
FR3037959B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr)	2016-01-19	2018-02-02	Les Laboratoires Servier	Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
CN109562107A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
EP4483875A2 (en)	2016-05-10	2025-01-01	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
TWI759316B (zh) *	2016-07-22	2022-04-01	法商施維雅藥廠	Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
JP7050744B2 (ja) *	2016-07-22	2022-04-08	レラボラトワールセルヴィエ	Ｂｃｌ－２阻害剤とｍｃｌ－１阻害剤との組み合わせ、その使用及び医薬組成物
GEP20217244B (en) *	2016-10-28	2021-04-26	Ag Novartis	Liposomal formulation for use in the treatment of cancer
WO2018126898A1 (zh) *	2017-01-05	2018-07-12	河南美泰宝生物制药有限公司	噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
UY37560A (es) *	2017-01-06	2018-07-31	Servier Lab	Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
US10765680B2 (en) *	2017-01-06	2020-09-08	Les Laboratories Servier	Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
EA039621B1 (ru) *	2017-06-09	2022-02-17	Ле Лаборатуар Сервье	Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
WO2018234433A1 (en)	2017-06-22	2018-12-27	Les Laboratoires Servier	Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
GB201712282D0 (en) *	2017-07-31	2017-09-13	Nodthera Ltd	Selective inhibitors of NLRP3 inflammasome
JP2020531427A (ja) *	2017-08-15	2020-11-05	アッヴィ・インコーポレイテッド	大環状ｍｃｌ−１阻害剤及び使用方法
UY37843A (es) *	2017-08-15	2019-03-29	Abbvie Inc	Inhibidores de mcl-1 macrocíclicos y métodos de uso
BR112020003200A2 (pt) *	2017-08-15	2020-10-06	AbbVie Deutschland GmbH & Co. KG	inibidores macrocíclicos de mcl-1 e métodos de uso
CN107573360B (zh) *	2017-10-27	2019-08-09	都创(上海)医药科技有限公司	一种多靶点小分子化合物s63845的制备方法
WO2019101144A1 (zh) *	2017-11-23	2019-05-31	北京赛林泰医药技术有限公司	Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) *	2017-12-21	2019-09-20	河南真实生物科技有限公司	噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) *	2018-09-29	2022-04-12	江苏恒瑞医药股份有限公司	嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) *	2018-10-15	2021-05-26	Servier Lab	Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh)	2018-11-14	2024-07-21	法商施維雅藥廠	Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
CN111187277B (zh) *	2018-11-14	2022-04-12	江苏恒瑞医药股份有限公司	噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
EP3891156B1 (en)	2018-12-06	2023-11-15	Les Laboratoires Servier	New crystalline forms of a thienopyrimidine as mcl-1 inhibitor
CN113453679A (zh)	2018-12-20	2021-09-28	C4医药公司	靶向蛋白降解
AU2020279979A1 (en) *	2019-05-20	2021-11-25	Les Laboratoires Servier	Mcl-1 inhibitor antibody-drug conjugates and methods of use
TW202114682A (zh)	2019-06-17	2021-04-16	法商施維雅藥廠	Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
AR119494A1 (es)	2019-07-29	2021-12-22	Servier Lab	DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
AR119493A1 (es)	2019-07-29	2021-12-22	Servier Lab	Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
AU2020358967A1 (en) *	2019-10-03	2022-05-19	1200 Pharma Llc	MCL1 inhibitors and uses thereof
CN113024578A (zh) *	2019-12-09	2021-06-25	首药控股(北京)有限公司	一种mcl1选择性抑制剂的多晶型物及其制备方法
CN113024577B (zh) *	2019-12-09	2023-06-30	首药控股(北京)股份有限公司	一种抗凋亡蛋白选择性抑制剂的制备方法
WO2022090443A1 (en)	2020-10-30	2022-05-05	Les Laboratoires Servier	Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
JP2023553811A (ja)	2020-11-24	2023-12-26	ノバルティスアーゲー	Ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用方法
EP4251208A1 (en)	2020-11-24	2023-10-04	Novartis AG	Mcl-1 inhibitor antibody-drug conjugates and methods of use
UY39609A (es)	2021-01-12	2022-08-31	Servier Lab	Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
EP4288434A1 (en)	2021-02-02	2023-12-13	Les Laboratoires Servier	Selective bcl-xl protac compounds and methods of use
WO2022216946A1 (en) *	2021-04-07	2022-10-13	California Institute Of Technology	Mcl1 inhibitors and uses thereof
WO2022255888A1 (en) *	2021-06-01	2022-12-08	Captor Therapeutics S.A.	Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
KR20240019330A (ko)	2021-06-11	2024-02-14	길리애드 사이언시즈, 인코포레이티드	Mcl-1 저해제와 항체 약물 접합체의 조합
AU2022291381A1 (en)	2021-06-11	2023-11-30	Gilead Sciences, Inc.	Combination mcl-1 inhibitors with anti-cancer agents
IL317101A (en)	2022-05-20	2025-01-01	Novartis Ag	Antibody-drug conjugates of anticancer compounds and methods of using them
WO2023225336A1 (en)	2022-05-20	2023-11-23	Novartis Ag	Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en)	2022-05-20	2023-11-23	Novartis Ag	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AU2023302094A1 (en)	2022-07-08	2025-01-23	Les Laboratoires Servier	New spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4008726A1 (de) *	1990-03-19	1991-09-26	Basf Ag	Thieno(2,3-d)pyrimidinderivate
KR101186678B1 (ko) *	2003-06-11	2012-09-27	젠션 리미티드	포타슘 채널 억제제로서의 티에노피리미딘 유도체
US20050187389A1 (en)	2004-01-13	2005-08-25	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US20050288906A1 (en)	2004-06-29	2005-12-29	Drennen James K Iii	Spectroscopic pharmacy verification and inspection system
MXPA06015223A (es)	2004-06-29	2007-11-09	Amgen Inc	Furanopirimidinas.
KR20070057792A (ko) *	2004-07-16	2007-06-07	선에시스 파마슈티컬스 인코포레이티드	오로라 키나아제 저해물질로서 유용한 티에노피리미딘
GB0423653D0 (en) *	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
US7576080B2 (en) *	2004-12-23	2009-08-18	Memory Pharmaceuticals Corporation	Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
JP5243960B2 (ja) *	2005-10-21	2013-07-24	ダウアグロサイエンシィズエルエルシー	殺菌活性を有するチエノ−ピリミジン化合物
AR064154A1 (es) *	2006-12-07	2009-03-18	Piramed Ltd	Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
DE102007027800A1 (de)	2007-06-16	2008-12-18	Bayer Healthcare Ag	Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
WO2009052145A1 (en) *	2007-10-16	2009-04-23	Wyeth	Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
KR101703941B1 (ko)	2008-11-10	2017-02-07	내셔날 헬스 리서치 인스티튜트	티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물
CA2803056C (en) *	2010-06-23	2017-05-16	Hanmi Science Co., Ltd.	Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2012044993A1 (en) *	2010-09-30	2012-04-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
CN102464667B (zh) *	2010-11-03	2014-06-04	中国科学院上海药物研究所	一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) *	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr)	2012-01-24	2014-02-21	Servier Lab	Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

2013
- 2013-12-23 FR FR1363500A patent/FR3015483B1/fr not_active Expired - Fee Related
2014
- 2014-12-08 JO JOP/2014/0353A patent/JO3193B1/ar active
- 2014-12-09 IL IL236143A patent/IL236143A/en active IP Right Grant
- 2014-12-10 CR CR20140569A patent/CR20140569A/es unknown
- 2014-12-10 PH PH12014000375A patent/PH12014000375B1/en unknown
- 2014-12-11 TN TN2014000516A patent/TN2014000516A1/fr unknown
- 2014-12-11 CA CA2875226A patent/CA2875226C/en active Active
- 2014-12-12 AU AU2014274644A patent/AU2014274644B2/en active Active
- 2014-12-12 AP AP2014008127A patent/AP2014008127A0/xx unknown
- 2014-12-15 DO DO2014000282A patent/DOP2014000282A/es unknown
- 2014-12-15 PE PE2014002444A patent/PE20151064A1/es active IP Right Grant
- 2014-12-17 CU CUP2014000143A patent/CU24309B1/xx unknown
- 2014-12-18 ZA ZA2014/09365A patent/ZA201409365B/en unknown
- 2014-12-18 MY MYPI2014703853A patent/MY185221A/en unknown
- 2014-12-18 CL CL2014003444A patent/CL2014003444A1/es unknown
- 2014-12-18 MX MX2014015854A patent/MX351581B/es active IP Right Grant
- 2014-12-19 JP JP2014257658A patent/JP5922215B2/ja active Active
- 2014-12-19 CN CN201410800069.2A patent/CN104725397B/zh active Active
- 2014-12-19 UA UAA201413661A patent/UA120341C2/uk unknown
- 2014-12-19 NI NI201400150A patent/NI201400150A/es unknown
- 2014-12-19 US US14/576,683 patent/US9670227B2/en active Active
- 2014-12-19 GE GEAP201413667A patent/GEP201706619B/en unknown
- 2014-12-22 EA EA201401292A patent/EA029601B1/ru unknown
- 2014-12-22 EP EP14199533.2A patent/EP2886545B1/en active Active
- 2014-12-22 UY UY0001035915A patent/UY35915A/es active IP Right Grant
- 2014-12-22 TW TW103144845A patent/TWI508969B/zh active
- 2014-12-22 PL PL14199533T patent/PL2886545T3/pl unknown
- 2014-12-22 WO PCT/EP2014/078947 patent/WO2015097123A1/en active Application Filing
- 2014-12-22 RS RS20160802A patent/RS55213B1/sr unknown
- 2014-12-22 RU RU2014151850/04A patent/RU2605403C2/ru active
- 2014-12-22 GT GT201400297A patent/GT201400297A/es unknown
- 2014-12-22 ES ES14199533.2T patent/ES2594377T3/es active Active
- 2014-12-22 SI SI201430061A patent/SI2886545T1/sl unknown
- 2014-12-22 SA SA114360144A patent/SA114360144B1/ar unknown
- 2014-12-22 MD MDA20140137A patent/MD4516C1/ro active IP Right Grant
- 2014-12-22 PT PT141995332T patent/PT2886545T/pt unknown
- 2014-12-22 BR BR102014032336-8A patent/BR102014032336B1/pt active IP Right Grant
- 2014-12-22 AR ARP140104847A patent/AR098906A1/es active IP Right Grant
- 2014-12-22 SG SG10201408563UA patent/SG10201408563UA/en unknown
- 2014-12-22 LT LTEP14199533.2T patent/LT2886545T/lt unknown
- 2014-12-22 ME MEP-2016-207A patent/ME02521B/me unknown
- 2014-12-22 HU HUE14199533A patent/HUE029654T2/en unknown
- 2014-12-22 DK DK14199533.2T patent/DK2886545T3/en active
- 2014-12-23 CO CO14282098A patent/CO7210068A1/es unknown
- 2014-12-23 KR KR1020140187349A patent/KR101636401B1/ko active IP Right Grant
2015
- 2015-10-28 HK HK15110667.4A patent/HK1209750A1/xx unknown
- 2015-12-16 HK HK15112389.7A patent/HK1211583A1/xx unknown
2016
- 2016-09-20 HR HRP20161203TT patent/HRP20161203T8/hr unknown
- 2016-09-22 CY CY20161100949T patent/CY1118058T1/el unknown
2017
- 2017-04-20 US US15/492,306 patent/US10278972B2/en active Active
2019
- 2019-03-08 US US16/296,766 patent/US20190201404A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UY35915A (es)	2015-07-31
PH12014000375B1 (en)	2017-10-11
JP2015129120A (ja)	2015-07-16
LT2886545T (lt)	2016-09-26
CN104725397A (zh)	2015-06-24
DK2886545T3 (en)	2016-09-19
PH12014000375A1 (en)	2016-06-13
CU24309B1 (es)	2018-01-10
AP2014008127A0 (en)	2014-12-31
TWI508969B (zh)	2015-11-21
HRP20161203T8 (hr)	2016-12-30
EP2886545A1 (en)	2015-06-24
KR101636401B1 (ko)	2016-07-05
EA201401292A2 (ru)	2015-06-30
CA2875226A1 (en)	2015-06-23
MX2014015854A (es)	2015-07-22
NZ702851A (en)	2016-05-27
AR098906A1 (es)	2016-06-22
FR3015483A1 (fr)	2015-06-26
BR102014032336A2 (pt)	2016-06-07
CU20140143A7 (es)	2016-07-29
SA114360144B1 (ar)	2015-10-08
ES2594377T3 (es)	2016-12-19
EA029601B1 (ru)	2018-04-30
NI201400150A (es)	2015-06-05
PE20151064A1 (es)	2015-08-08
MD20140137A2 (ro)	2015-06-30
HUE029654T2 (en)	2017-02-28
JO3193B1 (ar)	2018-03-08
BR102014032336B1 (pt)	2020-10-20
MD4516B1 (ro)	2017-09-30
GT201400297A (es)	2017-08-24
US9670227B2 (en)	2017-06-06
CR20140569A (es)	2016-07-01
PT2886545T (pt)	2016-08-25
GEP201706619B (en)	2017-02-10
EP2886545B1 (en)	2016-06-29
CL2014003444A1 (es)	2015-10-23
AU2014274644A1 (en)	2015-07-09
CA2875226C (en)	2018-03-13
US10278972B2 (en)	2019-05-07
MY185221A (en)	2021-04-30
IL236143A (en)	2017-02-28
MD4516C1 (ro)	2018-04-30
RU2014151850A (ru)	2016-07-20
CN104725397B (zh)	2017-11-28
DOP2014000282A (es)	2016-06-30
EA201401292A3 (ru)	2015-08-31
US20170216293A1 (en)	2017-08-03
JP5922215B2 (ja)	2016-05-24
TW201529583A (zh)	2015-08-01
KR20150073874A (ko)	2015-07-01
PL2886545T3 (pl)	2017-03-31
RU2605403C2 (ru)	2016-12-20
UA120341C2 (uk)	2019-11-25
CO7210068A1 (es)	2015-03-09
AU2014274644B2 (en)	2019-11-14
SI2886545T1 (sl)	2016-10-28
RS55213B1 (sr)	2017-02-28
MX351581B (es)	2017-10-20
ZA201409365B (en)	2021-07-28
US20150175623A1 (en)	2015-06-25
HRP20161203T1 (hr)	2016-11-04
HK1211583A1 (en)	2016-05-27
FR3015483B1 (fr)	2016-01-01
WO2015097123A1 (en)	2015-07-02
ME02521B (me)	2017-02-20
US20190201404A1 (en)	2019-07-04
SG10201408563UA (en)	2015-07-30
TN2014000516A1 (en)	2016-03-30
CY1118058T1 (el)	2017-06-28

Publication	Publication Date	Title
HRP20161203T8 (hr)	2016-12-30	Novi derivati tienopirimidina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
HK1254657A1 (zh)	2019-07-26	新的羥基酯衍生物、其製備方法以及含有它們的藥物組合物
HK1203506A1 (en)	2015-10-30	New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
HK1204623A1 (en)	2015-11-27	New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
IL243742B (en)	2019-06-30	New indolizine compounds, a process for their preparation and pharmaceutical preparations containing them
IL246406A0 (en)	2016-08-31	History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
HUP1300647A2 (hu)	2015-05-28	Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
IL239873B (en)	2018-12-31	The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
IL243012B (en)	2020-10-29	History of hydroxy-ethylene, their preparation and pharmaceutical preparations containing them
IL244102B (en)	2019-08-29	The history of cyclopentylamine, their preparation and pharmaceutical preparations containing them